Shuttle Pharmaceuticals Inc(SHPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SHPH Shuttle Pharmaceuticals Inc

Trading 03-20 09:38:43 EDT

0.9300

-0.0182

-1.92%

High0.9300	Low0.9300	Vol1.08K
Open0.9300	D1 Closing0.9482	Amplitude0.00%
Mkt Cap5.20M	Tradable Cap5.17M	Total Shares5.59M
T/O1.01K	T/O Rate0.02%	Tradable Shares5.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SHPH","market":"US","secType":"STK","nameCN":"Shuttle Pharmaceuticals Inc","latestPrice":0.93,"timestamp":1774013400275,"preClose":0.9482,"halted":0,"volume":1081,"delay":0,"changeRate":-0.019194262813752364,"floatShares":5563800,"shares":5591300,"eps":-11.15969,"marketStatus":"Trading","change":-0.0182,"latestTime":"03-20 09:38:43 EDT","open":0.93,"high":0.93,"low":0.93,"amount":1005.33,"amplitude":0,"askPrice":0.97,"askSize":1000,"bidPrice":0.9009,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-11.15969,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774036800000},"marketStatusCode":2,"adr":0,"listingDate":1661918400000,"exchange":"NASDAQ","adjPreClose":0.9482,"preHourTrading":{"tag":"盘前","latestPrice":0.9553,"preClose":0.9482,"latestTime":"08:31 EDT","volume":781,"amount":725.09230244,"timestamp":1774009917356,"change":0.0071,"changeRate":0.007488,"amplitude":0.036596},"postHourTrading":{"tag":"盘后","latestPrice":0.96,"preClose":0.9482,"latestTime":"19:48 EDT","volume":392,"amount":369.4208,"timestamp":1773964091474,"change":0.0118,"changeRate":0.012445,"amplitude":0},"volumeRatio":0.903662},"requestUrl":"/m/hq/s/SHPH","defaultTab":"news","newsList":[{"id":"2618134207","title":"Shuttle Pharmaceuticals closes USD 3.5 million public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618134207","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618134207?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:31","pubTimestamp":1773318692,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals announced a public offering expected to raise gross proceeds of about 3.5 million, before fees and expenses. The company agreed to issue 2,238,800 common shares and pre-funded warrants to buy 4,761,200 common shares. E.F. Hutton is serving as exclusive placement agent for the offering. Shuttle Pharmaceuticals said it plans to allocate up to 1.5 million of net proceeds to future marketing and the remainder to working capital and general corporate purposes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL6JZfkP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014005.SGD","LU0314104364.USD","LU2095319765.USD","BK4112","NDAQ","SHPH","BK4139","LU2210150020.SGD","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4588","SG9999014013.SGD"],"gpt_icon":0},{"id":"2618961466","title":"Shuttle Pharmaceuticals announces USD 3.5 million public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618961466","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618961466?lang=en_us&edition=fundamental","pubTime":"2026-03-11 05:01","pubTimestamp":1773176487,"startTime":"0","endTime":"0","summary":"Shuttle Pharma said it entered a securities purchase agreement for a public offering expected to raise about USD 3.5 million in gross proceeds. The offering includes 2.24 million shares of common stock and pre-funded warrants to buy 4.76 million shares. E.F. Hutton is acting as exclusive placement agent. Shuttle Pharma said it expects to use up to USD 1.5 million of the net proceeds for future marketing efforts, with the remainder for working capital and general corporate purposes. The offering is being made pursuant to a registration statement on Form S-1 available at www.sec.gov.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDG","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDLbsypyc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2612765495","title":"Shuttle Pharma FY2025 general and administrative expenses surge to USD 5.2–5.8 million from USD 1.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612765495","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612765495?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:21","pubTimestamp":1771366904,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. reported a preliminary net loss for full year 2025 in the range of USD 10.86 million to USD 12.08 million. The company recorded no revenue for the period. Research and development expenses are estimated between USD 3.42 million and USD 3.85 million, remaining relatively stable year-over-year. General and administrative expenses are expected between USD 5.23 million and USD 5.78 million, driven primarily by increased investor relations advertising costs of USD 3.6 million. Shuttle Pharmaceuticals anticipates a decrease in research and development activities pending future decisions on its preclinical and clinical drug development programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL282kGr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2608057813","title":"Shuttle Pharmaceuticals Extends Consulting Agreement With Interim Co-CEO at $20,000 Per Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2608057813","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608057813?lang=en_us&edition=fundamental","pubTime":"2026-02-03 06:21","pubTimestamp":1770070866,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has amended its consulting agreement with Number 2 Capital Corp., a Canadian entity owned by interim co-Chief Executive Officer Christopher Cooper. Effective September 11, 2025, the agreement extends the consulting term to August 1, 2026, with compensation set at $20,000 per month. The agreement requires a 40-hour work week and includes standard confidentiality and non-disclosure provisions. Either party may terminate the agreement with 30 days' notice, or immediately for cause.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL9JZFMB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2603529692","title":"Shuttle Pharmaceuticals Names Yuying Liang as Finance Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2603529692","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603529692?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:47","pubTimestamp":1768254420,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals named Yuying Liang as its next chief financial officer.Liang will succeed Chris Cooper, who will continue to serve as interim chief executive, the cancer treatment company said Monday.Liang, 35, has been working with the company via her company Yuying Liang Professional, where she has been performing bookkeeping, accounting and financial reporting.Liang is a certified public accountant who has worked with public and private companies across multiple sectors. Most recently, she was named chief financial officer of iSpecimen in December 2024.Liang also currently serves as chief financial officer of BlockchainK2, Goldhills Holding, Intact Gold, Kincora Copper, Transatlantic Mining and Ultra Brands. She is chief financial officer and director at Modern Plant Based Foods and Montego Resources.Shuttle plans to pay Liang a monthly fee of $15,000 plus taxes, it said.Separately, Sachin Pathigoda resigned from his position on the company's board of directors. The board ha","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2603526120","title":"BRIEF-Shuttle Pharmaceuticals Holdings Inc - Appoints Yuying Liang As CFO - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603526120","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603526120?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:20","pubTimestamp":1768252802,"startTime":"0","endTime":"0","summary":"BRIEF-Shuttle Pharmaceuticals Holdings Inc - Appoints Yuying Liang As CFO - SEC FilingJan 12  - SEC Filing:SHUTTLE PHARMACEUTICALS HOLDINGS INC - APPOINTS YUYING LIANG AS CFO - SEC FILINGSource text: [ID:n0001493152-26-001861]Further company coverage: SHPH.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0UG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2603526987","title":"Shuttle Pharmaceuticals Holdings Inc. Files Initial Beneficial Ownership Statement for CFO Yuying Liang","url":"https://stock-news.laohu8.com/highlight/detail?id=2603526987","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603526987?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:15","pubTimestamp":1768252553,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Yuying Liang, the company’s Chief Financial Officer, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL993RMP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Shuttle Pharmaceuticals Holdings Inc. Files Initial Beneficial Ownership Statement for CFO Yuying Liang","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2595758433","title":"Shuttle Pharmaceuticals Issues 320,496 Unregistered Shares in Asset Purchase Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2595758433","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595758433?lang=en_us&edition=fundamental","pubTime":"2025-12-30 05:06","pubTimestamp":1767042388,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has announced the accelerated issuance of 320,496 shares of its common stock as part of a private placement under the terms of an amended asset purchase agreement. The shares, issued at a value of $1.76 each, represent approximately 19.99% of the company’s outstanding common stock as of the closing date. The offering was made pursuant to exemptions from registration under the Securities Act, specifically Section 4, Rule 506, and Regulation S. The transaction’s remaining payment obligations will be settled in cash according to the agreement’s terms.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDLc5rVh7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2587585927","title":"BRIEF-Shuttle Pharmaceuticals Holdings Inc - Timothy Lorber Resigns As CFO Of Shuttle Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587585927","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587585927?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:34","pubTimestamp":1764369272,"startTime":"0","endTime":"0","summary":"BRIEF-Shuttle Pharmaceuticals Holdings Inc - Timothy Lorber Resigns As CFO Of Shuttle Pharmaceuticals - SEC FilingNov 28  - Shuttle Pharmaceuticals Holdings Inc SHPH.O:SHUTTLE PHARMACEUTICALS HOLDINGS INC - TIMOTHY LORBER RESIGNS AS CFO OF SHUTTLE PHARMACEUTICALS - SEC FILINGSHUTTLE PHARMACEUTICALS HOLDINGS INC - CHRISTOPHER COOPER ASSUMES ROLE OF CFO EFFECTIVE NOVEMBER 21, 2025 - SEC FILINGSHUTTLE PHARMACEUTICALS HOLDINGS INC - COOPER WILL SERVE IN THIS CAPACITY WHILE COM CONDUCTS SEARCH FOR PERMANENT CFOFurther company coverage: SHPH.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40IR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2587875830","title":"Shuttle Pharmaceuticals Holdings Inc - Timothy Lorber Resigns as CFO of Shuttle Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587875830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587875830?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:31","pubTimestamp":1764369115,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40IR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2587758307","title":"Shuttle Pharmaceuticals Holdings Inc - Cooper Will Serve in This Capacity While Com Conducts Search for Permanent CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2587758307","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587758307?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:31","pubTimestamp":1764369115,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40IR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2587475830","title":"Shuttle Pharmaceuticals Names Christopher Cooper as Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2587475830","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587475830?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:31","pubTimestamp":1764369099,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. announced that Timothy Lorber has resigned as Chief Financial Officer, effective immediately. Christopher Cooper, who is currently serving as Interim Chief Executive Officer, has assumed the additional role of Chief Financial Officer while the company searches for a permanent replacement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 28, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL86ZNGp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2586261198","title":"Shuttle Pharmaceuticals Announces Unregistered Sale of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2586261198","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586261198?lang=en_us&edition=fundamental","pubTime":"2025-11-27 01:29","pubTimestamp":1764178151,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has announced the unregistered sale of shares in connection with its recent asset acquisition. Under the terms of an Asset Purchase Agreement completed on November 20, 2025, the company may issue shares of its common stock as part of the consideration for the transaction. These shares will be offered pursuant to exemptions provided under Section 4 of the Securities Act, Rule 506, and Regulation S, and will not be registered under the Securities Act. The total number of shares issued will not exceed 19.99% of the company's outstanding common stock as of the closing date without shareholder approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the or","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL2qXY1c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2585112452","title":"Stocks to Watch: Shuttle Pharma, Butterfly Network, Captivision","url":"https://stock-news.laohu8.com/highlight/detail?id=2585112452","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585112452?lang=en_us&edition=fundamental","pubTime":"2025-11-22 07:38","pubTimestamp":1763768280,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals is discontinuing its cancer-drug trials after its partnership with Theradex ended. Shares fell 23% to $1.24 in after-hours trading Friday.Butterfly Network's director Lawrence Robbins bought 2.8 million shares. The stock gained 16% to $3.07 post market.Captivision said its chief executive would take on the responsibility of interim chief financial officer. The stock declined 4% to 75 cents after the market closed.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BFLY","CAPT","BK4082","BK4086","BK4139"],"gpt_icon":0},{"id":"2585125273","title":"Shuttle Pharmaceuticals Halts Ropidoxuridine Clinical Trials Amid Reorganization","url":"https://stock-news.laohu8.com/highlight/detail?id=2585125273","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585125273?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:06","pubTimestamp":1763759199,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has announced a corporate reorganization following the termination of its master agreement with Theradex Systems, Inc. As part of this process, the company will discontinue its clinical trials of Ropidoxuridine, immediately ending enrollment and beginning winddown activities in compliance with FDA requirements. Shuttle Pharmaceuticals has reached a settlement with Theradex, agreeing to pay $300,000 in final settlement of outstanding liabilities totaling approximately $557,000. The company also disclosed it will remain liable for about $750,000 under separate research site agreements with various hospitals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. publishe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDLbhKrdp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2585496071","title":"Shuttle Pharmaceuticals Closes Acquisition of Molecule.ai for $8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2585496071","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585496071?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:31","pubTimestamp":1763735460,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has completed the acquisition of the assets and liabilities of Molecule.ai, a Canadian artificial intelligence company focused on molecular discovery and drug development technologies. The agreement provides for a total purchase price of $8 million, paid in a mix of cash and Shuttle common stock, with an additional contingent payment of $2 million based on certain performance milestones. An initial payment of $3 million was made at closing. Molecule.ai's AI platform is expected to enhance Shuttle's capabilities in molecular modeling and predictive analytics, supporting the advancement of precision radiotherapy solutions and drug development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Ph","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL79ngCm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2585113776","title":"Lendway Shares Jump Nearly 20% After Hours — Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2585113776","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585113776?lang=en_us&edition=fundamental","pubTime":"2025-11-21 16:57","pubTimestamp":1763715420,"startTime":"0","endTime":"0","summary":"Lendway Inc. shares jumped nearly 20% in after-hours trading Thursday following a stock amendment filing and shareholder approval of an authorized share increase.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/21/Stock-Market-Growth-Vector-With-Green-Ca.jpeg?optimize=medium&dpr=2&auto=webp&width=120","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/21/Stock-Market-Growth-Vector-With-Green-Ca.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/11/48997002/lendway-shares-jump-nearly-20-after-hours-heres-why","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48997002/lendway-shares-jump-nearly-20-after-hours-heres-why","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SHPH","CFO","LDWY","BK4139","BK4009"],"gpt_icon":0},{"id":"2585118512","title":"Why Shuttle Pharmaceuticals (SHPH) Stock Surged Overnight?","url":"https://stock-news.laohu8.com/highlight/detail?id=2585118512","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585118512?lang=en_us&edition=fundamental","pubTime":"2025-11-21 15:52","pubTimestamp":1763711520,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals shares jumped 27.9% in after-hours trading Thursday after the company filed an S-1 registration statement and completed a $2.5 million private placement.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/21/shutterstock-2374266345.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/21/shutterstock-2374266345.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/11/48996580/why-shuttle-pharmaceuticals-shph-stock-surged-overnight","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48996580/why-shuttle-pharmaceuticals-shph-stock-surged-overnight","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2584717056","title":"Shuttle Pharmaceuticals Faces Nasdaq Delisting Risk Over Equity Shortfall","url":"https://stock-news.laohu8.com/highlight/detail?id=2584717056","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584717056?lang=en_us&edition=fundamental","pubTime":"2025-11-18 05:06","pubTimestamp":1763413581,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has announced that it was not in compliance with Nasdaq Listing Rule 5550, which requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders' equity. The company reported stockholders' equity of $1,394,161 as of September 30, 2025. However, Shuttle Pharmaceuticals believes it has regained compliance following a private placement on November 4, 2025, which raised approximately $2.5 million in gross proceeds. Nasdaq will continue to monitor the company's compliance, and if it is not maintained by the next periodic report, Shuttle Pharmaceuticals may face delisting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. pub","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL7MsZBY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2583548588","title":"Shuttle Pharmaceuticals Q3 EPS $(1.05) Up From $(39.75) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2583548588","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583548588?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:35","pubTimestamp":1763073356,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(1.05) per share. This is a 97.36 percent increase over losses of $(39.75) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48853181/shuttle-pharmaceuticals-q3-eps-1-05-up-from-39-75-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSYW.SI","NVIW.SI","USAW.SI","QID","QLD","PSQ",".IXIC","USJW.SI","SQQQ","SHPH","TQQQ","BK4139","NQmain","MNQmain"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shuttlepharma.com","stockEarnings":[{"period":"1week","weight":0.0236},{"period":"1month","weight":-0.122},{"period":"3month","weight":-0.4487},{"period":"6month","weight":-0.7682},{"period":"1year","weight":-0.9077},{"period":"ytd","weight":-0.4732}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.048599},{"month":2,"riseRate":0.5,"avgChangeRate":-0.170656},{"month":3,"riseRate":0.25,"avgChangeRate":-0.167089},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.023095},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.122933},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.116715},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.082532},{"month":8,"riseRate":0,"avgChangeRate":-0.223531},{"month":9,"riseRate":0.25,"avgChangeRate":-0.322851},{"month":10,"riseRate":0.25,"avgChangeRate":-0.104427},{"month":11,"riseRate":0.25,"avgChangeRate":-0.361431},{"month":12,"riseRate":0.75,"avgChangeRate":0.133405}],"exchange":"NASDAQ","name":"Shuttle Pharmaceuticals Inc","nameEN":"Shuttle Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shuttle Pharmaceuticals Inc(SHPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shuttle Pharmaceuticals Inc(SHPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shuttle Pharmaceuticals Inc,SHPH,Shuttle Pharmaceuticals Inc股票,Shuttle Pharmaceuticals Inc股票老虎,Shuttle Pharmaceuticals Inc股票老虎国际,Shuttle Pharmaceuticals Inc行情,Shuttle Pharmaceuticals Inc股票行情,Shuttle Pharmaceuticals Inc股价,Shuttle Pharmaceuticals Inc股市,Shuttle Pharmaceuticals Inc股票价格,Shuttle Pharmaceuticals Inc股票交易,Shuttle Pharmaceuticals Inc股票购买,Shuttle Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shuttle Pharmaceuticals Inc(SHPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shuttle Pharmaceuticals Inc(SHPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction